Reserpine

Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a601107
License data	US FDA: Reserpine
Pregnancy category	C
Routes of administration	Oral
ATC code	C02AA02 (WHO)
Legal status
Legal status	Rx-only (banned/discontinued in some countries)
Pharmacokinetic data
Bioavailability	50%
Metabolism	gut/liver
Elimination half-life	phase 1 = 4.5h, phase 2 = 271h, average = 33h
Excretion	62% feces / 8% urine
Identifiers
IUPAC name methyl (3β,16β,17α,18β,20α)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
CAS Number	50-55-5 Y
PubChem CID	5770
IUPHAR/BPS	4823
DrugBank	DB00206 Y
ChemSpider	5566 Y
UNII	8B1QWR724A
KEGG	D00197 Y
ChEBI	CHEBI:28487 Y
ChEMBL	ChEMBL772 Y
ECHA InfoCard	100.000.044
Chemical and physical data
Formula	C33H40N2O9
Molar mass	608.68 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES [H][C@]26C[C@@H](OC(=O)c1cc(OC)c(OC)c(OC)c1)[C@H](OC)[C@@H](C(=O)OC)[C@@]2([H])C[C@]5([H])c4[nH]c3cc(OC)ccc3c4CCN5C6
InChI InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 Y Key:QEVHRUUCFGRFIF-MDEJGZGSSA-N Y
.mw-parser-output .noboldfont-weight:normal   (verify)

Reserpine is a drug that is used for the treatment of high blood pressure, usually in combination with a thiazide diuretic or vasodilator.^[1] Large clinical trials have shown that combined treatment with reserpine plus a thiazide diuretic reduces mortality of people with hypertension. Although the use of reserpine as a solo drug has declined since it was first approved by the FDA in 1955,^[2] a review recommends use of reserpine and a thiazide diuretic or vasodilator in patients who do not achieve adequate lowering of blood pressure with first-line drug treatment alone.^[3] The reserpine-hydrochlorothiazide combo pill was the 17th most commonly prescribed of the 43 combination antihypertensive pills available In 2012.^[4]

The antihypertensive actions of reserpine are largely due to its antinoradrenergic effects, which are a result of its ability to deplete catecholamines (among other monoamine neurotransmitters) from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral vascular resistance.^[5]

At doses of 0.05 to 0.2 mg per day, reserpine is well tolerated;^[6] the most common adverse effect being nasal stuffiness.

Reserpine has also been used for relief of psychotic symptoms.^[7] A review found that in persons with schizophrenia, reserpine and chlorpromazine had similar rates of adverse effects, but that reserpine was less effective than chlorpromazine for improving a person's global state.^[8]

Mechanism of action[edit]

Reserpine irreversibly blocks the H⁺-coupled vesicular monoamine transporters, VMAT1 and VMAT2. VMAT1 is mostly expressed in neuroendocrine cells. VMAT2 is mostly expressed in neurons. Thus, it is the blockade of neuronal VMAT2 by reserpine that inhibits uptake and reduces stores of the monoamine neurotransmitters norepinephrine, dopamine, serotonin and histamine in the synaptic vesicles of neurons.^[9] VMAT2 normally transports free intracellular norepinephrine, serotonin, and dopamine in the presynaptic nerve terminal into presynaptic vesicles for subsequent release into the synaptic cleft ("exocytosis"). Unprotected neurotransmitters are metabolized by MAO (as well as by COMT), attached to the outer membrane of the mitochondria in the cytosol of the axon terminals, and consequently never excite the post-synaptic cell. Thus, reserpine increases removal of monoamine neurotransmitters from neurons, decreasing the size of the neurotransmitter pools, and thereby decreasing the amplitude of neurotransmitter release.^[10]

It may take the body days to weeks to replenish the depleted VMATs, so reserpine's effects are long-lasting.

Biosynthetic pathway[edit]

Reserpine is one of dozens of indole alkaloids isolated from the plant Rauvolfia serpentina.^[11] In the rauwolfia plant, tryptophan is the starting material in the biosynthetic pathway of reserpine, and is converted to tryptamine by tryptophan decarboxylase enzyme. Tryptamine is combined with secologanin in the presence of strictosidine synthetase enzyme and yields strictosidine. Various enzymatic conversion reactions lead to the synthesis of reserpine from strictosidine.^[12]

History[edit]

Reserpine was isolated in 1952 from the dried root of Rauwolfia serpentina (Indian snakeroot),^[13] which had been known as Sarpagandha and had been used for centuries in India for the treatment of insanity, as well as fever and snakebites^[14] — Mahatma Gandhi used it as a tranquilizer.^[15] It was first used in the United States by Robert Wallace Wilkins in 1950. Its molecular structure was elucidated in 1953 and natural configuration published in 1955.^[16] It was introduced in 1954, two years after chlorpromazine.^[17] The first total synthesis was accomplished by R. B. Woodward in 1958.^[16]

Reserpine was also highly influential in promoting the thought of a biogenic amine hypothesis of depression.^[18] Reserpine-mediated depletion of monoamine neurotransmitters in the synapses is often cited as evidence to the theory that depletion of the monoamine neurotransmitters causes subsequent depression in humans (c.f. monoamine hypothesis). However, this claim is not without controversy. The reserpine-induced depression is considered by some researchers to be a myth, while others claim that teas made out of the plant roots containing reserpine have a calming, sedative action that can actually be considered antidepressant.^[19] Notably, reserpine was the first compound shown to be an effective antidepressant in a randomized placebo-controlled trial.^[20]

Uses today[edit]

Seen is the drug reserpine in tablet form being counted out to fill a prescription in a pharmacy.

Medical Usage[edit]

A 2016 Cochrane review found reserpine to be as effective as other first-line antihypertensive drugs for lowering of blood pressure.^[21] The reserpine - thiazide diuretic combination is one of the few drug treatments shown to reduce mortality in randomized controlled trials: The Hypertension Detection and Follow-up Program,^[22] the Veterans Administration Cooperative Study Group in Anti-hypertensive Agents,^[23] and the Systolic Hypertension in the Elderly Program.^[24] Moreover, reserpine was included as a secondary antihypertensive option for patients who did not achieve blood pressure lowering targets in the ALLHAT study.^[25]

Reserpine was listed as an option by the JNC 7.^[26] In 1987, reserpine was considered a second-line adjunct agent for patients who were uncontrolled on a diuretic alone when cost was an issue.^[27]

It was previously used to treat symptoms of dyskinesia in patients suffering from Huntington's disease,^[28] but alternative medications are preferred today.^[29]

The daily dose of reserpine in antihypertensive treatment is as low as 0.05 to 0.25 mg. The use of reserpine as an antipsychotic drug had been nearly completely abandoned, but more recently it made a comeback as adjunctive treatment, in combination with other antipsychotics, so that more refractory patients get dopamine blockade from the other antipsychotic, and dopamine depletion from reserpine. Doses for this kind of adjunctive goal can be kept low, resulting in better tolerability. Originally, doses of 0.5 mg to 40 mg daily were used to treat psychotic diseases.

Doses in excess of 3 mg daily often required use of an anticholinergic drug to combat excessive cholinergic activity in many parts of the body as well as parkinsonism. For adjunctive treatment, doses are typically kept at or below 0.25 mg twice a day.

Veterinary and other[edit]

Reserpine may be used as a sedative for horses.

Another frequent use of reserpine is in the field of mass spectrometry where it is widely used as a reference standard owing to its availability, ease of ionization under electrospray conditions and stability in solution.

Reserpine is used as a long-acting tranquilizer to subdue excitable or difficult horses and has been used illicitly for the sedation of show horses, for-sale horses, and in other circumstances where a "quieter" horse might be desired.^[30]

Adverse effects[edit]

At doses of less than 0.2 mg/day, reserpine has few adverse effects, the most common of which is nasal congestion.^[31]

Reserpine can cause: nasal congestion, nausea, vomiting, weight gain, gastric intolerance, gastric ulceration (due to increased cholinergic activity in gastric tissue and impaired mucosal quality), stomach cramps and diarrhea are noted. The drug causes hypotension and bradycardia and may worsen asthma. Congested nose and erectile dysfunction are other consequences of alpha-blockade.^[32]

Central nervous system effects at higher doses (0.5 mg or higher) include drowsiness, dizziness, nightmares, Parkinsonism, general weakness and fatigue.
^[33]

High dose studies in rodents found reserpine to cause fibroadenoma of the breast and malignant tumors of the seminal vesicles among others. Early suggestions that reserpine causes breast cancer in women (risk approximately doubled) were not confirmed. It may also cause hyperprolactinemia.^[32]

Reserpine passes into breast milk and is harmful to breast-fed infants, and should therefore be avoided during breastfeeding if possible.^[34]

It may produce an excessive decline in blood pressure at doses needed for treatment of anxiety, depression, or psychosis.^[35]

References[edit]

External links[edit]

• NLM Hazardous Substances Databank – Reserpine


• 
  PubChem Substance Summary: Reserpine National Center for Biotechnology Information.


• The Stork Synthesis of (−)-Reserpine